BioVenture
VC Fund
Suzhou, China
BioVenture is a VC fund in Suzhou focused on Health Care and Biotechnology. Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
- Total investments:
- 191
- Last investment:
- Lead investor:
- 33%
- Fund size:
- $204M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BioVenture invests in
Stages BioVenture invests in
Countries BioVenture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Round size
- Seed
- $7.9M–$41M
- Series A
- $4.4M–$47M
- Series B
- $7.1M–$73M
Investment Focus
Industry
- Health Care 81 (42%)
- Biotechnology 71 (37%)
- Medical 68 (36%)
- Pharmaceutical 40 (21%)
- Biopharma 36 (19%)
Stage
- Series A 66 (35%)
- Series B 38 (20%)
- Seed 22 (12%)
- Venture - Series Unknown 21 (11%)
- Series C 14 (7%)
Country
- China 143 (75%)
- United States 11 (6%)
- Hong Kong 2 (1%)
- Taiwan 1 (1%)
- Germany 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erik Hoppe
Executive Partner
|
Executive Partner | Total investments: 2 | Find email | |
|
Chen Jie
Founding Partner
|
Founding Partner | Total investments: 5 | Find email | |
Gaojian Ning
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
Haihua Huang
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
Jacky Chen
General Manager
|
General Manager | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inno Medicine
|
Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis. | $119.2M / Series D / Sep 09, 2026 | |
AusperBio
|
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $120M / Series C / Aug 27, 2026 | |
SiranBio
|
SiranBio is a biotechnology that develops innovative siRNA drugs. | $59.5M / Series A / Aug 20, 2026 | |
Navi Therapeutics
|
Navi Therapeutics is a biotechnology company focused on developing next-generation antibody-drug conjugates and antibody-based therapeutics for oncology | Series A / Aug 18, 2026 | |
|
Mingche Technology
|
Mingche Technology is an innovative ophthalmic medical device company. | Series A / Aug 06, 2026 | |
Beyond Therapeutics
|
Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | $29.6M / Series A / Jul 30, 2026 | |
CORE Biomedicine
|
CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M / Series A / Jul 28, 2026 | |
|
Silicon Core
|
Silicon Core specializes on massive code models, AI-powered programming robots, and corporate private deployment. | Angel / Jul 07, 2026 | |
|
Xingyuanzhi Robotics
|
Xingyuanzhi Robotics strives to develop multimodal spatial intelligence systems and a universal embodied brain capable of comprehending and interacting with the physical world. | $147.8M / Seed / Jun 03, 2026 | |
|
Zhenyu Bio
|
Zhenyu Bio is a biopharmaceutical service provider that specializes in the development of next-generation universal cell therapy products, such as in vivo CAR-T and innovative universal therapeutic cell vaccines. | $14.7M / Series A / May 27, 2026 | |
| See all 191 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BioVenture invest in?
BioVenture invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 191 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BioVenture's check size?
BioVenture typically joins rounds of $7.9M–$41M at Seed, $4.4M–$47M at Series A and $7.1M–$73M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioVenture participates in.
How do I contact BioVenture?
Public channels for BioVenture include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioVenture?
The team at BioVenture includes Erik Hoppe (Executive Partner), Chen Jie (Founding Partner) and Gaojian Ning (Investment Director), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
